

Tofogliflozin

Chemical Properties


CAS No. : 903565-83-3

Formula: C22H26O6

Molecular Weight: 386.44

Appearance:

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Tofogliflozin is a highly specific inhibitor of sodium/glucose cotransporter 2 (SGLT2) (Kis: 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2. IC50s: 2.9/14.9/6.4 nM (human/rat/mouse SGLT2)).
Targets(IC50)	Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5877 mL	12.9386 mL	25.8772 mL
5 mM	0.5175 mL	2.5877 mL	5.1754 mL
10 mM	0.2588 mL	1.2939 mL	2.5877 mL
50 mM	0.0518 mL	0.2588 mL	0.5175 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. *Br J Pharmacol.* 2013 Oct;170(3):519-31.

Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. *Xenobioti*

Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. *J Pharmacol Exp Ther.* 2012 Jun;341(3):692-701.

Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. *Am J Physiol Endocrinol Metab.* 2013 Feb 15;304(4):E414-23.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_email:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481